Truist analyst Richard Newitter lowered the firm’s price target on Zimmer Biomet to $115 from $148 and keeps a Hold rating on the shares as part of a broader research note on MedTech. The sector continues to trade down on fear of exposure to GLP-1s, and even good Q3 earnings may not matter amid a GLP-1 sector overhang, the analyst tells investors in a research note. While Truist continues to believe that the dramatic GLP1-driven sector pullback is likely overdone and that “narrative” is driving indiscriminate selling more so than a tangible fundamental impact, it’s hard to say when/if the GLP-1 overhang will subside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZBH:
- Becton, Medtronic, Twist, Zimmer added to ‘Tactical Outperform’ list at Evercore
- Zimmer Biomet price target lowered to $125 from $146 at Citi
- TD Cowen medical devices analyst to hold analyst/industry conference call
- Zimmer Biomet ‘very confident’ in guidance for 2H23
- Zimmer Biomet ‘very pleased’ with how Q3 is progressing